key: cord-0873793-n72x7yvi
authors: Van, Jeremy; Kramer, Jason; Economou, Ioannis
title: Acute Pancreatitis with Colonic Pseudo-obstruction in a Patient with COVID-19
date: 2022-03-01
journal: Case Rep Gastroenterol
DOI: 10.1159/000521918
sha: bddfa4582afbbba2fe239a976241d49ea2b90e98
doc_id: 873793
cord_uid: n72x7yvi

Angiotensin-converting enzyme 2 receptor, the receptor used by severe acute respiratory syndrome coronavirus-2 (COVID-19) to infect cells, is found not only on respiratory epithelium but also in the small bowel, large bowel, and pancreas. There have been rare reports of acute pancreatitis (AP) in COVID-19 patients without an obvious etiology other than the underlying viral syndrome. We present a patient who was admitted with COVID-19 and developed AP and colonic pseudo-obstruction.

In December 2019, severe acute respiratory syndrome coronavirus-2 (COVID-19) was first reported in Wuhan, China. Since then, there are over 124 million cases confirmed worldwide [1] . Common symptoms include fever, cough, myalgia, and shortness of breath [2] . Patients also have reported gastrointestinal symptoms. Around 66 of 254 people confirmed to have COVID-19, from December 2019 to February 2020 in China, were noted to have gastrointestinal symptoms such as nausea, vomiting, diarrhea, and abdominal pain [3] . Positive stool samples with COVID-19 have been found, supporting the possibility of fecal-oral transmission [4] . COVID-19 infects cells via angiotensin-converting enzyme 2 receptors (ACE2Rs) found not only on respiratory epithelium but also on gut enterocytes [5] . These receptors are also found on pancreatic islet cells and exocrine glands [6] . Infection of duodenal epithelium with further transmission to the pancreatic duct, acinar, and islet cells is a possible pathogenic mechanism [7] . Cases of acute pancreatitis (AP) have been rarely described in patients actively infected with COVID-19. We report a case of AP in a COVID-19 patient with abdominal pain, initially thought to be primarily from colonic pseudo-obstruction, which persisted after endoscopic colonic decompression.

A 66-year-old male with a past medical history of pulmonary embolism, hypertension, type II diabetes mellitus, and chronic kidney disease presented to the hospital with a 3-day history of generalized weakness and shortness of breath. He had no significant past surgical or family history. His social history was remarkable for distant heroin use but no past smoking or alcohol history. Home medications included rivaroxaban, buprenorphine/naloxone, insulin glargine, and metoprolol. His vital signs on arrival included BP 147/79, HR 92, Temp 102.6°F, RR 17, and SpO2 94% on room air. Physical examination was remarkable for mild crackles in the bilateral lower lung fields. His WBC count was 1.18 K/μL. The HIV antigen and antibody were negative. His blood urea nitrogen and creatinine (Cr) were 40 mg/dL and 2.67 mg/dL (baseline Cr 2.0 mg/dL). His liver function tests (LFTs) were within normal range. Urine drug screen and blood and urine cultures were negative. COVID-19 nasopharyngeal PCR was positive. His inflammatory markers were remarkable for C-reactive protein 43.7 mg/L and ferritin 931 ng/mL. The chest radiograph demonstrated bilateral lower lobe airspace opacities. He was treated for COVID-19 with supportive management. On day 3 of hospitalization, he complained of epigastric abdominal pain and distension. An abdominal radiography (KUB) showed 9 mm dilated gas-filled large bowel (shown in Fig. 1 ). Of note, computed tomography (CT) abdomen/pelvis (AP) from 20 days prior did not show significant colonic dilation. Potassium, magnesium, and thyroid-stimulating hormone were within normal range. His LFTs were still in normal range. CT-AP without IV contrast demonstrated a diffusely dilated large bowel without a transition point (shown in Fig. 2) ; the gallbladder and pancreas were unremarkable. Tap water enemas and bisacodyl suppositories were administered with 2-3 bowel movements daily, but he continued to have abdominal pain. From day 6 to 8, repeat KUBs continued to have significant colonic dilatation with decreased frequency in bowel movements. IV erythromycin was trialed without improvement. Neostigmine therapy was not administered in the setting of significant renal impairment. On day 9, he was started on total parenteral nutrition a b Fig. 1. a-b Abdominal radiograph (one view anterior-posterior) demonstrating a significantly dilated (9 mm diameter) gas-filled large bowel (black arrows and bars) concerning for colonic ileus. with a repeat KUB demonstrating large bowel dilatation and cecal dilation greater than 10 mm (shown in Fig. 3a) . Also, the patient had no BM for >24 h. Thus, an endoscopic colonic decompression was performed with improvement in dilation on KUB (shown in Fig. 3b ). Postprocedure, he was less distended on abdominal examination, but he continued to have epigastric abdominal pain. Lipase and amylase were 959 U/L (normal range 0-52 U/L) and 425 U/L (normal range 25-115 U/L); LFTs were in normal range and stable, and Cr, calcium, and triglycerides were 2.04 mg/dL, 8.7 mg/dL, and 74 mg/dL. On day 11, the patient was hemodynamically stable, afebrile with only mild pain to palpation on his abdominal exam. His lipase downtrended from 959 to 739 U/L, C-reactive protein was stable at 38.4 mg/L, and WBC had normalized from 1.18 to 8.83 K/μL. By day 15, the patient continued to be hemodynamically stable with supportive management, was weaned off total parenteral nutrition, tolerated a soft diet, and had minimal abdominal pain. He was discharged to a skilled nursing facility on day 19. injury, and indirect damage via systemic inflammatory and immune-mediated cellular responses [8, 9] . The latter two mechanisms have been proposed for COVID-19-induced AP [9]. A direct cytopathic mechanism is possible as there is ACE2R expression in small-bowel enterocytes and the pancreas [5] . Large bowel enterocytes also express ACE2R [10]. Our patient developed Ogilvie's syndrome, which has been described in a few COVID-19 patients [11] . As the patient concurrently had pancreatitis and Ogilvie syndrome, it is plausible both syndromes were impacted by COVID-19. In a retrospective study evaluating COVID-19 versus non-COVID-19 patients with AP, there was 0.39% prevalence of AP among both groups. Of the COVID-19 patients, there was a 0.27% prevalence. Regardless of COVID-19 status, AP prevalence was low. But COVID-19 may still play a role in AP pathogenesis as 69% of cases were "idiopathic" [12] . Although, in another similar retrospective study, comparison of AP frequency in COVID-19 versus non-COVID-19 patients resulted in an odds ratio of 0.41, questioning if COVID-19 has a role in pathogenesis. Also, interestingly, the rise in lipase and amylase was more moderate, and abdominal pain was less frequent in COVID-19 AP patients, making diagnosis in this patient population potentially difficult [13] .

Per the revised Atlanta classification, AP diagnosis requires two out of three criteria: severe abdominal pain consistent with AP, serum lipase or amylase at least three times above the upper limit of normal, and imaging findings consistent with AP [14]. Our patient had severe epigastric abdominal pain and 18× and 4× the upper limit of normal of lipase and amylase, respectively. CT-AP was performed without IV contrast, limiting gallbladder and pancreas examination, as the patient had acute kidney injury. Although CT has a lower sensitivity of detecting gallstones compared to ultrasound, our patient never had elevated LFTs or jaundice [15] nor did he have an alcohol use history or hypertriglyceridemia. Our patient's etiology of AP was highly suspicious for COVID-19.

This case report highlights the importance of considering and evaluating for pancreatitis in COVID-19 patients presenting with abdominal pain. Further studies are needed to elucidate the potential relationship, pathogenesis, and incidence of AP in patients infected with COVID-19. 

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Effect of Gastrointestinal symptoms in patients with COVID-19

First case of 2019 novel coronavirus in the United States

SARS-CoV-2 productively infects human gut enterocytes

SARS-COV-2 associated acute pancreatitis: cause, consequence or epiphenomenon? Pancreatology

COVID-19 and acute pancreatitis: examining the causality